TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A review of existing research says women with polyendocrine metabolic ovarian syndrome (PMOS), formerly called PCOS, may face greater risk of changes in memory, thinking and brain health associated with Alzheimer’s disease and related dementias. The authors say the evidence does not establish that PMOS itself causes dementia; insulin resistance, obesity and other metabolic conditions may help explain the possible link.
A review of existing research has found a possible association between polyendocrine metabolic ovarian syndrome (PMOS) and changes in memory, thinking and brain health linked to Alzheimer’s disease and related dementias. Published in the Journal of the Endocrine Society, the review does not show that PMOS causes dementia; its authors say metabolic conditions such as insulin resistance and obesity may account for much of the observed association.
The authors searched PubMed for research from the database’s inception through October 2025. Reviewing that evidence, they concluded that people with PMOS may be more likely to experience changes in cognition and brain health, as well as biological pathways associated with Alzheimer’s disease and related dementias. The paper is a review of existing studies, not a trial that followed participants to measure whether they later developed dementia.
The review describes reports of mild but reproducible difficulties in executive function and memory among people with PMOS, alongside structural and functional brain differences. Those findings may point to areas of concern, but they do not establish that a person with PMOS will develop Alzheimer’s disease or dementia, nor do they show that the syndrome independently produces those conditions.
The authors identify insulin resistance, obesity and other metabolic disorders as possible pathways connecting PMOS with cognitive risk. The review’s account says the relationship may be mediated by these common coexisting conditions rather than by PMOS itself. The study was funded by the Foundation for Research and Education Excellence. Its authors include researchers affiliated with Tehran University of Medical Sciences, the University of Alabama at Birmingham, the University of Southern California and the Foundation for Research and Education Excellence.
Metabolic Health May Explain the Link
The review matters because it brings attention to a possible connection between a syndrome affecting reproductive and metabolic health and later-life concerns about memory and dementia. PMOS is reported to affect 10% to 15% of women worldwide and is associated with a range of health issues, including diabetes, cardiovascular disease, stroke, depression and anxiety. A clearer account of how these conditions relate could help researchers identify which factors are associated with cognitive changes.
For now, the findings do not support treating PMOS as a proven cause of Alzheimer’s disease or using the review to predict an individual’s dementia risk. The emphasis on metabolic conditions matters: it points researchers toward possible shared mechanisms and raises the need to distinguish the effect of PMOS from the effects of obesity, insulin resistance and related health problems. The review offers a research direction, not a new diagnosis or prevention recommendation.
metabolic health supplements for women
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From PCOS to PMOS Research
The condition discussed in the paper was formerly known as polycystic ovary syndrome (PCOS) and is referred to in the source material as polyendocrine metabolic ovarian syndrome, or PMOS. The review frames it as a condition with effects that can extend beyond reproductive health, including metabolic and psychological concerns. It also notes that the condition may affect males in different ways.
The paper, by Mina Amiri and colleagues, is titled Potential links between PCOS/PMOS and Alzheimer disease and related dementias and appeared in the Journal of the Endocrine Society in 2026. Its approach was to assess published evidence rather than collect new clinical data. Ricardo Azziz, a study co-author affiliated with the University of Alabama at Birmingham, said the authors see value in studying how the two disorders may be related and in identifying shared pathways that could inform future research.
“Current evidence suggests that any association between PMOS and Alzheimer’s disease and dementia is likely mediated by metabolic comorbidities, particularly insulin resistance and obesity, rather than an independent effect of PMOS itself.”
— Ricardo Azziz, study co-author
As an affiliate, we earn on qualifying purchases.
Cause and Individual Risk Remain Unknown
The review does not establish cause and effect, quantify how much dementia risk may differ for people with PMOS, or show that the association persists after accounting for metabolic health and other factors. The source material does not provide a single risk estimate, a defined period of follow-up, or evidence that managing PMOS prevents Alzheimer’s disease or dementia.
The authors describe gaps in the evidence and call for further research. It remains unclear which mechanisms, if any, are most important; whether particular groups with PMOS face different levels of risk; and how the reported cognitive and brain findings relate to dementia diagnoses over time. These findings should not be used as an individual prognosis or medical advice.
As an affiliate, we earn on qualifying purchases.
Research Needed to Test the Association
The review identifies future research as the next step, particularly work that can separate possible effects of PMOS from those of insulin resistance, obesity and other metabolic conditions. Studies tracking participants over time could help determine whether cognitive differences are associated with later dementia diagnoses and clarify how large any difference in risk may be.
No specific follow-up study or timetable is stated in the supplied report. Until stronger evidence is available, the findings remain a research signal rather than proof of a direct link or a change to clinical guidance. People making decisions about their health should consult a qualified health professional.
cognitive health supplements for women
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Does PMOS cause Alzheimer’s disease?
No causal link is established. The review reports a possible association and says metabolic conditions, including insulin resistance and obesity, may help explain it.
What did the researchers review?
The authors searched PubMed for published evidence available through October 2025. This was a review of existing research, not a new clinical trial or a study following a new group of participants.
What cognitive changes did the review describe?
The review cites reports of mild difficulties in executive function and memory, as well as structural and functional brain differences. These findings do not mean that everyone with PMOS will develop dementia.
How common is PMOS?
The source report says PMOS affects an estimated 10% to 15% of women worldwide. The review also notes that the condition may affect males in different ways.
Does this review change medical advice?
The supplied report does not describe a change to clinical guidance or establish a prevention strategy. The findings are preliminary evidence for further study; consult a qualified health professional about individual health decisions.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
